44 results
424B3
APRE
Aprea Therapeutics Inc
30 Apr 24
Prospectus supplement
7:34am
to enrich our pipeline with novel targets in synthetic lethality and cancer treatment. Together with our expertise in small molecule drug discovery
8-K
EX-99.2
APRE
Aprea Therapeutics Inc
10 Apr 24
IND for APR-1051 has been cleared; details on planned Phase 1 first in human trial (ACESOT-1051) presented
4:15pm
and WEE1 inhibitors are integral to stopping DDR and are emerging targets for cancer cell death Builds on scientific innovation led by Aprea founder and key
8-K
EX-99.2
APRE
Aprea Therapeutics Inc
26 Mar 24
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
8:15am
leads to mitotic catastrophe and cell death ATR and WEE1 inhibitors are integral to stopping DDR and are emerging targets for cancer cell death Builds
424B3
egl2knuapvar vxv
9 Feb 24
Prospectus supplement
12:00am
8-K
EX-99.1
6w7t90 hd
6 Feb 24
Other Events
5:01pm
424B3
fvvoj67c 6hzp8
5 Feb 24
Prospectus supplement
12:00am
8-K
EX-99.2
1iexngbf45agutts pmn
4 Jan 24
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
4:16pm
8-K
EX-99.1
rxxm16y9s5zdy
9 Nov 23
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
4:15pm
8-K
58e3xeqm9o2hmjk
16 Oct 23
Other Events
5:29pm
8-K
EX-99.1
0afyfjpr
16 Oct 23
Other Events
5:29pm
8-K
EX-99.2
msejcvmrkic35j
10 Aug 23
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
7:36am
8-K
EX-99.2
hgwie8i52jx2rhtx3sg4
15 May 23
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
12:00am
8-K
EX-99.1
ixhygj3dee xk
8 May 23
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
8:45am